secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-09-23T11:10:29+00:00
Accession:  0001104659-26-109809
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata receives $3.7M additional DoW funding for AP-SA02 Phase 3; total $32.4M
------------------------------------------------------------------------------

- Received $3.7M non-dilutive funding from U.S. Department of War for AP-SA02 Phase 3 development.
- Cumulative DoW funding under award now $32.4M, adding to $28.7M previously provided.
- Funding supports adjunctive treatment for complicated S. aureus bacteremia (MSSA/MRSA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926109809/0001104659-26-109809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926109809/tm2625977d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-109809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer